News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-22 5:56:6 am AIM ImmunoTech Announces Release of the Next CEO Corner Segment GlobeNewsWire
2024-03-20 6:25:0 am AIM ImmunoTech Announces Release of the Next CEO Corner Segment GlobeNewswire
2024-03-15 5:45:0 am AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity GlobeNewswire
2024-03-07 5:45:0 am AIM ImmunoTech Announces Launch of CEO Corner Platform GlobeNewswire
2024-02-29 5:45:0 am AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update GlobeNewswire
2024-02-14 5:55:0 am AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer GlobeNewswire
2024-02-08 5:50:0 am AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions GlobeNewswire
2024-01-24 6:10:0 am AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire
2024-01-22 5:55:0 am AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information